Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis

Abraham Fisher; Rachel Brandeis; Rachel Haring; Naomi Eshhar; Eliahu Heldman; Yishai Karton; Orli Eisenberg; Haim Meshulam; Daniele Marciano; Nira Bar-Ner; Zipora Pittel

doi:10.1016/S0928-4257(99)80001-1

Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis

Abraham Fisher
, Rachel Brandeis
, Rachel Haring
, Naomi Eshhar
, Eliahu Heldman
, Yishai Karton
, Orli Eisenberg
, Haim Meshulam
, Daniele Marciano
, Nira Bar-Ner
, Zipora Pittel

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

M1 selective agonists from the AF series (e.g. AF102B, AF150(S)), via m1 muscarinic receptors, activate distinct signal transductions, enhance amyloid precursors proteins secretion from transfected cells and primary cell cultures, show neurotrophic effects and are beneficial in a variety of animal models for Alzheimer's disease. Such m1 agonists may be effective in the treatment and therapy of Alzheimer's disease.

Original language	English
Pages (from-to)	337-340
Number of pages	4
Journal	Journal of Physiology Paris
Volume	92
Issue number	5-6
DOIs	https://doi.org/10.1016/S0928-4257(99)80001-1
State	Published - 1 Jan 1998
Externally published	Yes

Keywords

AF series
Alzheimer's disease
M1 agonists

ASJC Scopus subject areas

General Neuroscience
Physiology (medical)

Access to Document

10.1016/S0928-4257(99)80001-1

Cite this

@article{f871d3ea78fd4b44aa2b08980c4ea24a,

title = "Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis",

abstract = "M1 selective agonists from the AF series (e.g. AF102B, AF150(S)), via m1 muscarinic receptors, activate distinct signal transductions, enhance amyloid precursors proteins secretion from transfected cells and primary cell cultures, show neurotrophic effects and are beneficial in a variety of animal models for Alzheimer's disease. Such m1 agonists may be effective in the treatment and therapy of Alzheimer's disease.",

keywords = "AF series, Alzheimer's disease, M1 agonists",

author = "Abraham Fisher and Rachel Brandeis and Rachel Haring and Naomi Eshhar and Eliahu Heldman and Yishai Karton and Orli Eisenberg and Haim Meshulam and Daniele Marciano and Nira Bar-Ner and Zipora Pittel",

year = "1998",

month = jan,

day = "1",

doi = "10.1016/S0928-4257(99)80001-1",

language = "English",

volume = "92",

pages = "337--340",

journal = "Journal of Physiology Paris",

issn = "0928-4257",

publisher = "Elsevier Masson s.r.l.",

number = "5-6",

}

TY - JOUR

T1 - Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease

T2 - An unifying hypothesis

AU - Fisher, Abraham

AU - Brandeis, Rachel

AU - Haring, Rachel

AU - Eshhar, Naomi

AU - Heldman, Eliahu

AU - Karton, Yishai

AU - Eisenberg, Orli

AU - Meshulam, Haim

AU - Marciano, Daniele

AU - Bar-Ner, Nira

AU - Pittel, Zipora

PY - 1998/1/1

Y1 - 1998/1/1

N2 - M1 selective agonists from the AF series (e.g. AF102B, AF150(S)), via m1 muscarinic receptors, activate distinct signal transductions, enhance amyloid precursors proteins secretion from transfected cells and primary cell cultures, show neurotrophic effects and are beneficial in a variety of animal models for Alzheimer's disease. Such m1 agonists may be effective in the treatment and therapy of Alzheimer's disease.

AB - M1 selective agonists from the AF series (e.g. AF102B, AF150(S)), via m1 muscarinic receptors, activate distinct signal transductions, enhance amyloid precursors proteins secretion from transfected cells and primary cell cultures, show neurotrophic effects and are beneficial in a variety of animal models for Alzheimer's disease. Such m1 agonists may be effective in the treatment and therapy of Alzheimer's disease.

KW - AF series

KW - Alzheimer's disease

KW - M1 agonists

UR - https://www.scopus.com/pages/publications/0032441386

U2 - 10.1016/S0928-4257(99)80001-1

DO - 10.1016/S0928-4257(99)80001-1

M3 - Article

C2 - 9789833

AN - SCOPUS:0032441386

SN - 0928-4257

VL - 92

SP - 337

EP - 340

JO - Journal of Physiology Paris

JF - Journal of Physiology Paris

IS - 5-6

ER -

Novel m1 muscarinic agonists in treatment and delaying the progression of Alzheimer's disease: An unifying hypothesis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this